NCT01950325View on ClinicalTrials.gov

VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 22, 2013

Primary Completion Date

August 20, 2015

Study Completion Date

August 20, 2015

Conditions
HIV-1 InfectionNeutralizing AntibodyMonoclonal AntibodyViral LoadHIV Antibodies
Interventions
BIOLOGICAL

VRC-HIVMAB060-00-AB

VRC01 Human Monoclonal Antibody

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01950325 - VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected... | Biotech Hunter | Biotech Hunter